Abstract
Heart failure with preserved ejection fraction (HFpEF) is a major public health challenge, affecting millions worldwide and placing a significant burden on healthcare systems due to high hospitalization rates and limited treatment options. HFpEF is characterized by impaired cardiac relaxation, or diastolic dysfunction. However, there are no therapies that directly treat the primary feature of the disease. This is due in part to the complexity of normal diastolic function, and the challenge of isolating the mechanisms responsible for dysfunction in HFpEF. Without a clear understanding of the mechanisms driving diastolic dysfunction, progress in treatment development has been slow. In this review, we highlight three key areas of molecular dysregulation directly underlying impaired cardiac relaxation in HFpEF: altered calcium sensitivity in the troponin complex, impaired phosphorylation of myosin-binding protein C (cMyBP-C), and reduced titin compliance. We explore how targeting these pathways can restore normal relaxation, improve diastolic function, and potentially provide new therapeutic strategies for HFpEF treatment. Developing effective HFpEF therapies requires precision targeting to balance systolic and diastolic function, avoiding both upstream non-specificity and downstream rigidity. This review highlights three rational molecular targets with a strong mechanistic basis and potential for therapeutic success.
Introduction
Heart failure (HF) is a clinical syndrome wherein the heart is unable to execute its primary function of efficiently circulating blood throughout the body in keeping with physiological demands (). HF is broadly characterized according to the percent of the ventricular volume displaced by each contraction, known as the ejection fraction (EF). In HF with reduced ejection fraction (HFrEF), the primary deficit is the reduced ability of the pump to propel blood forward during systole. HF with preserved EF (HFpEF), meanwhile, is mediated by impaired extensibility and relaxation of the heart muscle during diastole which leads to decreased ventricular filling and elevated filling pressure (; ; ).
Systolic and diastolic function are interrelated, and as such, EF-based classification is an oversimplification of the underlying pathophysiology (; ). In both HFrEF and HFpEF, the clinical syndrome results from insufficient cardiac output, which includes fluid buildup in the lungs leading to impaired oxygenation, chronic activation of the renin-angiotensin-aldosterone system, and lack of cardiac reserve that results in exercise intolerance (; ; ; ). These symptoms of impaired pump function exacerbate one another in a vicious cycle, ultimately reducing quality of life and significantly increasing morbidity and mortality (; ).
HF poses a massive global public health problem, impacting over 64 million people worldwide (). In the US alone, 6.7 million adults have HF, projected to increase to over 8 million by 2030, accounting for 3% of the total population (; ). Approximately half of HF patients are diagnosed with either HFrEF or HFpEF, with the proportion of HFpEF patients projected to increase due to rising rates of HFpEF risk factors like diabetes, obesity, and aging of the population (; Tsao et al., 2018). While several therapies exist for HFrEF that demonstrate mortality benefit, the effectiveness of these therapies decreases with increasing EF (), such that there are very few evidence-based options available for treating HFpEF (). At the core of HF is the heart’s inability to meet the body’s physiological demands for blood flow. Addressing this requires either increasing the heart’s functional capacity or reducing its workload. The few therapies available for HFpEF do not directly address the underlying diastolic dysfunction that limits the capacity of the heart (; ). Current first-line treatment for HFpEF is use of SGLT2 inhibitors, whose primary effect is on the kidney rather than the heart (Vaduganathan et al., 2022; Solomon et al., 2022; ). While SGLT2 inhibitors were shown to decrease the risk of HF-associated hospitalization, they have not shown a mortality benefit versus placebo (Vaduganathan et al., 2022; Solomon et al., 2022; ). Furthermore, the mechanism behind their cardiovascular benefit is unknown. The current management strategy for HFpEF patients involves attempting to mitigate comorbidities, for example by using GLP-1 agonist medications to treat underlying obesity that may have precipitated HFpEF (; ; ; ). Otherwise, current therapies such as diuretics, mineralocorticoid receptor antagonists, and combination angiotensin receptor/neprilysin inhibitors serve only to mitigate the symptoms of dysfunction by reducing the demand on the heart (). A mechanism-based approach that addresses the root cause of dysfunction, i.e. impaired filling, therefore remains an urgent yet unmet clinical need.
Determinants of cardiac function
Understanding the determinants of cardiac relaxation is essential for identifying therapeutic targets to restore diastolic function. The pressure-volume relation of the cardiac cycle described below is reviewed in detail in textbooks by Katz () and Klabunde (). Briefly, each cardiac cycle begins following an electrical impulse that reaches the myocardium and initiates pressure development. At this stage, pressure in the left ventricle (LV) is above that in the left atrium (LA), so the mitral valve is closed, yet remains below the pressure in the aorta, so the aortic valve is also closed (Figure 1A, position 1). The ventricle undergoes isovolumic contraction as force generation against the closed valves causes pressure in the LV to rise. When pressure exceeds that in the aorta, the aortic valve opens and the forceful contraction of the LV drives ejection (Figure 1A, position 2). During early ejection, pressure continues to rise even as the volume of blood in the LV decreases. LV pressure reaches its peak during late ejection, then begins to fall as the volume in the LV reaches its nadir (known as end systolic volume, or ESV; Figure 1A position 3). Once pressure falls below that in the aorta, the aortic valve closes and the LV relaxes isovolumically. This isovolumic relaxation causes pressure to fall, eventually falling below the pressure in the LA. This pressure gradient results in the opening of the mitral valve and the flow of blood from LA to LV (Figure 1A, position 4). Pressure remains low during early filling as the recoil and untwisting of the contracted LV sucks blood into the LV (Yellin et al., 1990; ), and the compliance of the LV wall partially resists pressure increase with passive stretch. During late filling, pressure in the LV begins to rise as the momentum of the LV muscle forcefully re-lengthening wanes, and the wall stretches further beyond its resting length. At the end of filling, LA contraction provides a final push of blood into the LV. At this point, rising ventricular pressure matches atrial pressure, leading to closure of the mitral valve, and returning the LV to the isovolumic state prior to the next contraction. The same events occur in the right atrium and ventricle, though at much lower pressures.
FIGURE 1
The organ-level events in the cardiac cycle are driven by corresponding molecular events within cardiomyocytes. Excitation-contraction coupling (ECC) is the process by which an electrical event initiates the contractile action of a muscle cell. Contraction is initiated by a sharp increase in intracellular calcium concentration, known as the calcium transient (Figure 2; box 1) (; ). This correlates with the arrival of the electrical impulse. Voltage-gated L-type calcium channels open to allow entry of a small amount of calcium, which serves as the stimulus for a much greater release of stored calcium from the sarcoplasmic reticulum in a process known as calcium-induced calcium release (CICR). Calcium strongly activates the thin filament within sarcomeres. Prior to calcium release, a population of myosin cross-bridges exist in a weakly bound state, primed for strong binding contingent upon exposure of actin binding sites (; ). At normal diastolic calcium levels, these actin binding sites are blocked by tropomyosin, under the regulation of the troponin complex consisting of cardiac troponin C (cTnC), troponin I (cTnI), and troponin T (cTnT) (; Tardiff, 2011; ). When calcium levels rise at the start of systole, binding of calcium to cTnC promotes the activated state of the thin filament (Yamada et al., 2020; ). In the activated state, cTnI binds cTnC and stabilizes cTnC-calcium binding, while cTnT shifts tropomyosin to expose the myosin binding sites on actin (). As long as the thin filament is in this activated state, primed myosin cross-bridges will strongly bind with actin and generate force, causing cardiac muscle to contract (; ). The amount of calcium released during CICR as well as the binding kinetics and affinity of cTnC for calcium help control the magnitude and rate of thin filament activation, and thus the magnitude and rate of force generation in early systole.
FIGURE 2
The activation level of the thick filament and priming of the thick filament just prior to calcium release also contribute to the rate of early pressure development and shortening (; ). The level of activation of the thick filament is regulated in part by a thick-filament associated protein cardiac myosin binding protein C (cMyBP-C) (; ; Suay-Corredera and Alegre-Cebollada, 2022). When the phosphorylation level of cMyBP-C is low, cMyBP-C promotes the OFF state of the thick filament with myosin heads tethered to the thick filament backbone, reducing the population that exist in the weakly bound state that are primed for binding (Zoghbi et al., 2004; ; Zoghbi et al., 2008). When phosphorylation is high, cMyBP-C relieves this inhibition and promotes the ON state of the thick filament in which myosin heads project away from the thick filament backbone and are primed for interaction with the actin filament (; ; ). When calcium levels are low just prior to the initiation of a new contraction, cMyBP-C also primes the thin filament for activation through its interactions with actin, sensitizing the thin filament to myosin binding (; ; ).
The calcium transient, as its name implies, exists only for a short period of time. Calcium is quickly removed from the cytosol by reuptake into the sarcoplasmic reticulum via the ATPase SERCA2a and extrusion from the cell via the sodium-calcium exchanger NCX1. These and other calcium handling processes are reviewed in detail elsewhere (; ). Importantly, peak cytosolic calcium concentration occurs well before peak ventricular pressure is attained, at which point calcium binding has waned to nearly diastolic levels (Figure 2) (; ; ). Thus, late ejection is attributable to intrinsic sarcomere processes that potentiate force generation. Cooperative mechanisms within the sarcomere maintain thin filament activation beyond the decline of the calcium transient. Strongly bound cross-bridges increase the affinity of cTnC for calcium, prolonging activation (; ; ). Additionally, strongly bound cross-bridges act as a “foot in the door” of the thin filament regulatory unit, and sterically block tropomyosin from covering adjacent myosin binding sites on actin (; ; Tobacman, 1996). Perhaps the most important mechanism by which ejection is prolonged is the activity of cMyBP-C. Its importance is underlined by studies demonstrating that ejection time is severely truncated when cMyBP-C is absent from sarcomeres (; Tong et al., 2008; ; Stelzer et al., 2006a). As mentioned previously in the context of priming the sarcomere prior to contraction, cMyBP-C again contributes to the continued activation of the thin filament as calcium levels wane during late systole (; ; ; ). Its interactions with the thin filament also create a viscous drag that slows shortening, reducing shortening-induced deactivation (Walcott et al., 2015; Weith A. et al., 2012). Overall, cMyBP-C acts as a brake on the system, slowing and prolonging the force generating state of the sarcomere (Figure 2; box 3).
Late ejection is terminated as sarcomere shortening induces strain on active cross-bridges, resulting in shortening-induced deactivation (; ). This force ultimately overpowers the dissipating cooperative mechanisms that maintain activation of the sarcomere, and strongly-bound cross-bridges detach (). Once detachment occurs, re-binding is prevented in the absence of calcium, as the thin filament’s regulatory unit returns to its position blocking the myosin binding sites on actin.
As the forces favoring shortening of the sarcomere decline, the forces favoring re-lengthening take over. One such force at the level of the sarcomere is the potential energy stored during contraction by the compression of the sarcomere protein titin (; ). Titin is a giant protein that spans the thick filament from Z-disk to M-band and serves as a myofibril scaffold for the correct positioning and stoichiometry of other thick filament proteins (; Tonino et al., 2017). In addition, titin’s extensible I-band segment functions as a molecular spring that contributes to the rate of cardiac relaxation (). Titin’s extensible I-band does not begin exactly at the edge of the Z-disk. Instead, a short segment of titin adjacent to the Z-disk binds to the thin filament, making it stiff and inextensible (). This structure enables titin’s extensible region to act as a bi-directional spring. When sarcomeres are stretched beyond their slack length, titin generates a force that pulls the Z-disks toward each other. Conversely, when sarcomeres shorten below the slack length, titin exerts a force that pushes the Z-disks apart—this force is known as the restoring force.
The restoring force is engaged during systole when sarcomere shortening occurs below the equilibrium volume and the stored potential energy is expected to contribute to the suction force essential for the early filling phase of the heart () Thus, when contraction ends, the restoring force of titin re-lengthening drives relaxation (Figure 2; box 4). This forceful re-lengthening generates a force in the opposite direction from contraction, resulting in a drop in ventricular pressure as cardiac muscle relaxes. Elements outside the sarcomere also contribute to the restoring force following contraction. Compression of microtubules causes them to buckle, adopting a high-energy conformation that bears the compressive load of contraction (; ).
Another force promoting negative pressure generation in the ventricle is the release of stored momentum from contraction in the form of ventricular untwisting (Figure 2; box 5) (; ). Myofibrils in the epi- and endocardium are arranged in opposite directions to one another such that contraction results in twisting of the ventricle–a motion similar to wringing a towel (; ). The momentum of this twist is reversed following contraction and ventricular untwisting contributes to ventricular suction during relaxation. As such, the force and velocity of shortening during systole are themselves important determinants of diastolic function.
Once pressure in the ventricle has fallen below that in the atrium, blood begins to fill the ventricle. As the volume in the ventricle increases, the elastance of the myocardium determines the corresponding change in pressure. Titin stiffness is the primary determinant of this passive pressure during filling (). Other elements such as the cytoskeleton (including microtubules, actin, and intermediate filaments) as well as the extracellular matrix (ECM) also contribute to stiffness. While titin alone is the primary determinant of elastic passive force, the cytoskeletal elements are relevant to the viscous component (; ). Pressure remains low during early filling as titin’s early high compliance allows for large changes in volume with correspondingly small changes in pressure (; ). As ventricular volume reaches the threshold of titin’s compliance, titin is the primary determinant of muscle stiffness (; ). Thus during late filling (Figure 2; box 6), ventricular pressure rises slightly with the rise in volume. This relationship is characterized by the slope of the end diastolic pressure-volume relation, or EDPVR (Figure 1B).
The stretch of the ventricle experienced at end diastole is a primary determinant of muscle contractility in the subsequent cardiac cycle, according to the well-described Frank-Starling mechanism (). Thus diastolic performance, and the volume of blood that is able to enter the ventricle during filling (end diastolic volume, or EDV), is itself an important determinant of systolic function–a reciprocal of the relationship between systolic performance and diastolic performance. This exemplifies the cyclic and interrelated nature of cardiac function. The pressure gradient that exists between atrium and ventricle is the driving force behind ventricular filling. The larger the pressure gradient, the greater the driving force. The greater the driving force, the faster the flow, and thus greater the volume of blood that can enter the ventricle before the pressure equalizes and filling ceases due to closure of the valve. By keeping pressure in the ventricle low, and even generating negative pressure during early relaxation, titin’s compliant, spring-like qualities allow for efficient filling of the ventricle without requiring elevated atrial pressure ().
Dysfunction in HFpEF
The organ-level diastolic dysfunction that underlies HFpEF is attributable to dysfunction of the different sarcomere processes that drive normal relaxation at baseline and in response to stress (; ; van der Velden and Stienen, 2019; ). HFpEF can develop in the context of a variety of different whole-body perturbations, including diabetes, obesity, and aging (; ; ). What these different conditions have in common is ultimately dysfunction of cardiac mechanics that become limiting. Potential culprits underlying this mechanical dysfunction include signaling pathways involving different kinases and growth factors. Recently, modulation of receptor tyrosine kinase signaling was found to promote cardiac relaxation (). The PKA/PKG signaling axis in particular is known to be dysregulated in the setting of HF (; ; ). Targets of this axis include proteins described above that regulate the cardiac cycle, including cTnI, cMyBP-C, and titin.
Under physiologic conditions, activation of PKA signaling by adrenergic stress results in cTnI phosphorylation (; ; ; ; ). Phosphorylation of cTnI decreases the calcium sensitivity of cTnC (). In the face of the increased calcium release that simultaneously occurs during adrenergic stress, the rate of force development still increases, but the decreased sensitivity helps prevent over-activation of the thin filament and tunes de-activation to match the overall faster rate of contraction (). In HFpEF, cTnI phosphorylation is decreased (), so cTnC has a higher calcium sensitivity than required for the contractile state. This leads to prolonged activation that encroaches on the time needed for pressure to fully drop during diastole.
cMyBP-C phosphorylation by PKA decreases its affinity for both actin and myosin (; ; ; Tong et al., 2008). While unphosphorylated cMyBP-C acts as a brake on the system, constraining and slowing force generation, phosphorylation of cMyBP-C is like stepping on the gas (; ; Weith AE. et al., 2012). Decreased interaction between phosphorylated cMyBP-C and myosin relieves inhibition on myosin heads, resulting in greater activation of the thick filament and more cross-bridges added to the force generating pool (; ). While decreased interaction between cMyBP-C and actin diminishes the activating effect on the thin filament, this effect is dwarfed by the strongly activating effect of increased calcium release during normal adrenergic signaling (). Decreased interaction between cMyBP-C and actin thus has a net accelerating effect because of the reduction in viscous drag that is otherwise imposed when cMyBP-C links the thick and thin filaments (Walcott et al., 2015). PKA phosphorylation of cMyBP-C has been shown to accelerate overall cross-bridge cycling kinetics (Weith A. et al., 2012; ; Weith AE. et al., 2012; Stelzer et al., 2006b). Because cMyBP-C contributes to the potentiation of force generation during late systole, acceleration of cycling kinetics results in shortened ejection (). This is necessary for tuning the mechanics of contraction and relaxation to fit the externally fixed time between heartbeats. In HFpEF, cMyBP-C phosphorylation is decreased (), and the normal acceleration of contraction kinetics in response to stress is blunted. Ejection is inappropriately prolonged, leaving inadequate time for relaxation. Additionally, the slower contractile kinetics may limit the extent and momentum of myocardial twisting during systole that is necessary for optimal re-lengthening during diastole.
Titin is also a target for a variety of signaling pathways, including PKA and PKG (; ; ; ; Yamasaki et al., 2002). During adrenergic stress, phosphorylation of titin increases its compliance, limiting the passive force developed during filling (; ; Yamasaki et al., 2002). Additionally, different titin isoforms exhibit different inherent stiffness (), and isoform expression is regulated by signaling pathways that are perturbed in HFpEF (). In HFpEF, titin phosphorylation is decreased, and expression of the stiffer isoform increases (; Zile et al., 2015). These factors contribute to the increased overall myocardial stiffness observed in HFpEF hearts, and help explain the increased slope of the EDVPR (Figure 1B). While titin is the primary determinant of passive stiffness in the heart, other cellular and extracellular elements also contribute and are the determinants of the viscous component (). Increased ventricle stiffness in HFpEF is also the result of excess collagen deposition in the ECM and increased cardiac fibrosis (Zile et al., 2015). Further, microtubule expression and tyrosination is altered in HFpEF, leading to increased LV stiffness (; ).
The decreased diastolic filling that occurs due to altered contractile kinetics, slowed relaxation, and increased stiffness results in limitation of stroke volume (Figure 1B) (). Stroke volume represents the blood that is supplied to the body with each heartbeat, and must supply the metabolic demands of all tissues. A stiffer heart with a slowed rate of relaxation and less total time for relaxation will fill with less blood. In order to fill a stiffer heart with an elevated ventricular pressure during filling, a correspondingly higher atrial pressure is required to maintain the gradient to drive filling. Decreases in stroke volume are the ultimate source of cardiac insufficiency in HFpEF, and elevations in left atrial and pulmonary vascular pressure directly and indirectly result in comorbidities such as atrial fibrillation and pulmonary hypertension (Zakeri et al., 2013; ; ). Therapeutic interventions should therefore target the factors that result in decreased stroke volume and elevated filling pressure in order to ameliorate this insufficiency and restore cardiac function. This highlights cTnI, cMyBP-C, and titin as potentially ideal targets.
Therapeutic outlook
The therapeutic strategies currently employed in HFpEF are only tangentially aimed at addressing the underlying myofilament dysfunction that is at the root of the syndrome. Attempts have been made to target the dysregulated PKG signaling axis that is likely in part responsible for myofilament dysfunction, for example via phosphodiesterase inhibition (; ). However, this target lies far upstream in the signaling pathway and thus lacks specificity, which likely explains its lack of clinical success. Attempts to target the PKA signaling pathway via beta-blockers have similarly been unsuccessful in HFpEF (). While SGLT2 inhibitors have shown initial promise in HFpEF, the mechanism underlying their cardiac effects remains unclear. Given that SGLT2 is not significantly expressed in the myocardium, it seems likely that the effect is systemic or off-target, rather than targeted to the sarcomere (; ; ). At present, there are no sarcomere-based therapies approved for use in HFpEF. The myosin-inhibiting small molecule mavacamten has shown promise in a mouse model of HFpEF (). However, targeting myosin to address cardiac dysfunction has proven challenging in the past, for example with the development of novel inotropes aimed at improving function in HFrEF such as omecamtiv mecarbil (Teerlink et al., 2011; ; ). The drawback of targeting myosin itself is that physiologically, cardiac myosin is required to perform two contradictory functions. Drugs that directly promote the contractile function of myosin do so at the expense of relaxation. On the other hand, drugs that inhibit contraction in order to promote relaxation induce systolic dysfunction. More promising are examples of therapeutic approaches that target proteins that are known to be altered in HFpEF whose native function involves tuning the sarcomere to appropriately match systolic and diastolic function. These targets include the proteins described in this review: the troponin complex, cMyBP-C, and titin.
Given that one of the primary molecular defects in HFpEF is inappropriately increased calcium sensitivity of the sarcomere as a result of impaired cTnI phosphorylation, reducing calcium sensitivity is a therapeutic goal. Attempts to target the troponin complex have involved methods that decrease calcium sensitivity to reverse this dysfunction. The small molecule W7 decreases the calcium sensitivity of force development in cardiac muscle by decreasing the binding of cTnI to cTnC (). This agent has been tested in pre-clinical disease models characterized by known hyper calcium-sensitive sarcomere states, such as hypertrophic and restrictive cardiomyopathy (Thompson et al., 2016). Novel protein engineering techniques have also been investigated to alter the calcium sensitivity of the thin filament. In a model of decreased contractility induced by myocardial infarction, using AAV9-based gene therapy to deliver cTnC with a calcium-sensitizing mutation therapeutically enhanced cardiac function (; ). The success of this approach in a HFrEF model suggests that it could be further developed to apply to models of HFpEF by engineering mutations that counteract the increased calcium sensitivity that contributes to HFpEF pathophysiology. Whatever the approach, targeting the troponin complex would be expected to mitigate diastolic dysfunction by shortening early ejection and promoting faster deactivation of the thin filament, resulting in improved coupling of systolic and diastolic performance (Figure 2; box 2).
Decreased phosphorylation of cMyBP-C in HFpEF results in slowed cross-bridge cycling kinetics, decreased myosin head recruitment, and increased viscous drag (; Tong et al., 2008; ; ; Stelzer et al., 2006b). Therefore, therapies that either promote or mimic the phosphorylated state of cMyBP-C would be expected to restore function. Currently, there are no small molecules with cMyBP-C as their target. However, the recent development of a high-throughput screen for identifying compounds that alter cMyBP-C binding makes this a promising avenue for further investigation (; ; ; Wong et al., 2024). There are challenges inherent in the development of small molecules to target such subtle and pleiotropic effects as cMyBP-C phosphorylation. The advent of gene therapy provides an opportunity for more rational design of therapies by using protein engineering. Similar to the approach developed for delivering a mutated version of cTnC with altered calcium sensitivity, mutated versions of cMyBP-C that structurally and functionally mimic the phosphorylated state could be used to tune the sarcomere. The result of therapies that successfully target cMyBP-C would be acceleration of shortening velocity, shortening of late ejection, and enhancement of cooperative deactivation. Accelerating shortening velocity harnesses the mechanical coupling between systolic and diastolic function to improve relaxation by providing more stored momentum during systole that will be released in diastole. Overall acceleration of kinetics and enhancement of cooperative deactivation shortens the duration of ejection, providing more time during a given cardiac cycle for adequate relaxation and filling (Figure 2; box 3).
Decreased titin compliance is one of the primary sarcomeric factors underlying diastolic dysfunction in HFpEF (Tamargo et al., 2023). Stiffer titin results in a steeper EDVPR, which contributes to decreased EDV as described above. Increased titin stiffness in HFpEF is the result of alterations in phosphorylation and titin isoform expression (; Zile et al., 2015; Tamargo et al., 2023; ). Studies in rat cardiomyocyte cultures indicate that the glucose-lowering drug metformin and the growth factor neuregulin-1 enhance ERK1/2 activity, leading to increased phosphorylation at multiple titin sites (). The potential therapeutic benefits of metformin were explored in a mouse model with HFpEF-like symptoms (Slater et al., 2018). In these metformin-treated mice, phosphorylation of titin was increased. Although metformin did not affect extracellular matrix stiffness, it reduced titin-based passive stiffness, normalized left ventricular diastolic dysfunction, and improved exercise tolerance (Slater et al., 2018). Therapeutic strategies aimed at restoring titin compliance by promoting expression of more compliant isoforms have also been successful in preclinical animal models of HFpEF (; ). The splicing factor RBM20 has been shown to mediate shifts to stiffer titin isoforms, and blocking the function of this splicing factor in transgenic animals resulted in improved compliance (). In a mouse model of HFpEF and in human engineered heart tissue, using antisense oligonucleotides to inhibit RBM20 resulted in increased expression of compliant titin isoforms and improvements in in vivo and in vitro measures of diastolic function (). The success of this approach illustrates the principal role that titin alterations play in HFpEF pathophysiology, and demonstrates that targeting titin to directly address this pathophysiology is beneficial. By increasing titin compliance in HFpEF hearts, the early phase of relaxation is accelerated (Figure 2; boxes 4 and 5), filling occurs at a lower pressure (Figure 2; box 6), and the slope of the EDVPR is normalized (Figure 1B).
Conclusion
Normal cardiac diastolic function involves a high degree of complexity and requires precise interaction in time and space between countless moving parts, resulting in emergent phenomena that cannot be understood in isolation (). Added to this is the highly complex physiological milieu of comorbidities in which HFpEF develops. It is therefore not surprising that the challenge of effectively treating HFpEF remains unsolved. Such a complex process requires highly precise targeting. Too far upstream, as in the case of agents aimed at whole signaling pathways, and the target is too nonspecific with unintended off target effects that may ultimately exacerbate dysfunction. Too far downstream, as in the case of direct myosin modulators, and the target lacks the flexibility to encompass the multiple different modes of activity required for proper coupling of systolic and diastolic function. The targets proposed in this review represent promising intermediates, and should be the focus of therapy development with the best chance of success.
Statements
Author contributions
KD: Writing–original draft, Writing–review and editing. AS: Writing–original draft, Writing–review and editing. HG: Funding acquisition, Writing–original draft, Writing–review and editing. KC: Funding acquisition, Writing–original draft, Writing–review and editing. JS: Conceptualization, Funding acquisition, Writing–original draft, Writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants awarded by the NIH National Heart, Lung, and Blood Institute (NHLBI) grants R01HL146676 (JS, KS), R01HL153236 (JS), R35HL144998 (HG), R01HL148785 (KS), R01HL163977 (KS), T32GM152319 (KD), and the American Heart Association (AHA) grants 2022TPA961478 (JS) and 24PRE1187710 (KD).
Acknowledgments
Figures 1, 2 were created with a licensed version of BioRender.com.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AboonabiA.McCauleyM. D. (2024). Myofilament dysfunction in diastolic heart failure. Heart Fail Rev.29 (1), 79–93. 10.1007/s10741-023-10352-z
2
AlgülS.SchuldtM.MandersE.JansenV.SchlossarekS.de Goeij-de HaasR.et al (2023). EGFR/IGF1R signaling modulates relaxation in hypertrophic cardiomyopathy. Circ. Res.133 (5), 387–399. 10.1161/CIRCRESAHA.122.322133
3
Al-KhayatH. A.KenslerR. W.SquireJ. M.MarstonS. B.MorrisE. P. (2013). Atomic model of the human cardiac muscle myosin filament. Proc. Natl. Acad. Sci. U. S. A.110 (1), 318–323. 10.1073/pnas.1212708110
4
AnkerS. D.ButlerJ.FilippatosG.FerreiraJ. P.BocchiE.BöhmM.et al (2021). Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med.385 (16), 1451–1461. 10.1056/NEJMoa2107038
5
AshikagaH.CriscioneJ. C.OmensJ. H.CovellJ. W.IngelsN. B. (2004). Transmural left ventricular mechanics underlying torsional recoil during relaxation. Am. J. Physiol-Heart Circ. Physiol.286 (2), H640–H647. 10.1152/ajpheart.00575.2003
6
BellS. P.NylandL.TischlerM. D.McNabbM.GranzierH.LeWinterM. M. (2000). Alterations in the determinants of diastolic suction during pacing tachycardia. Circ. Res.87 (3), 235–240. 10.1161/01.res.87.3.235
7
BersD. M. (2002). Cardiac excitation–contraction coupling. Nature415 (6868), 198–205. 10.1038/415198a
8
BiesiadeckiB. J.DavisJ. P.ZioloM. T.JanssenP. M. L. (2014). Tri-modal regulation of cardiac muscle relaxation; intracellular calcium decline, thin filament deactivation, and cross-bridge cycling kinetics. Biophys. Rev.6 (3), 273–289. 10.1007/s12551-014-0143-5
9
BiesiadeckiB. J.KobayashiT.WalkerJ. S.SolaroR. J.de TombeP. P. (2007). The troponin C G159D mutation blunts myofilament desensitization induced by troponin I Ser23/24 phosphorylation. Circ. Res.100 (10), 1486–1493. 10.1161/01.RES.0000267744.92677.7f
10
BorbélyA.Falcao-PiresI.van HeerebeekL.HamdaniN.EdesI.GavinaC.et al (2009). Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ. Res.104 (6), 780–786. 10.1161/CIRCRESAHA.108.193326
11
BorlaugB. A.PaulusW. J. (2011). Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur. Heart J.32 (6), 670–679. 10.1093/eurheartj/ehq426
12
BozkurtB.AhmadT.AlexanderK.BakerW. L.BosakK.BreathettK.et al (2024). HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure society of America. J. Card. Fail14. 10.1016/j.cardfail.2024.07.001
13
BrunelloE.FusiL. (2024). Regulating striated muscle contraction: through thick and thin. Annu. Rev. Physiol.86, 255–275. 10.1146/annurev-physiol-042222-022728
14
BunchT. A.GuhathakurtaP.ThompsonA. R.LepakV. C.CarterA. L.ThomasJ. J.et al (2023). Drug discovery for heart failure targeting myosin-binding protein C. J. Biol. Chem.299 (12), 105369. 10.1016/j.jbc.2023.105369
15
BurnsA. T.La GercheA.PriorD. L.MacIsaacA. I. (2009). Left ventricular untwisting is an important determinant of early diastolic function. JACC Cardiovasc Imaging2 (6), 709–716. 10.1016/j.jcmg.2009.01.015
16
CaiF.HwangP. M.SykesB. D. (2018). Structural changes induced by the binding of the calcium desensitizer W7 to cardiac troponin. Biochemistry57 (46), 6461–6469. 10.1021/acs.biochem.8b00882
17
CaporizzoM. A.ChenC. Y.BediK.MarguliesK. B.ProsserB. L. (2020). Microtubules increase diastolic stiffness in failing human cardiomyocytes and myocardium. Circulation141 (11), 902–915. 10.1161/CIRCULATIONAHA.119.043930
18
CaporizzoM. A.ProsserB. L. (2022). The microtubule cytoskeleton in cardiac mechanics and heart failure. Nat. Rev. Cardiol.19 (6), 364–378. 10.1038/s41569-022-00692-y
19
ChungC. S.GranzierH. L. (2011). Contribution of titin and extracellular matrix to passive pressure and measurement of sarcomere length in the mouse left ventricle. J. Mol. Cell Cardiol.50 (4), 731–739. 10.1016/j.yjmcc.2011.01.005
20
ClelandJ. G. F.BuntingK. V.FlatherM. D.AltmanD. G.HolmesJ.CoatsA. J. S.et al (2018). Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur. Heart J.39 (1), 26–35. 10.1093/eurheartj/ehx564
21
CowieM. R.FisherM. (2020). SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol.17 (12), 761–772. 10.1038/s41569-020-0406-8
22
DavisJ. P.ShettigarV.TikunovaS. B.LittleS. C.LiuB.SiddiquiJ. K.et al (2016). Designing proteins to combat disease: cardiac troponin C as an example. Arch. Biochem. Biophys.601, 4–10. 10.1016/j.abb.2016.02.007
23
DavisJ. P.TikunovaS. B. (2008). Ca(2+) exchange with troponin C and cardiac muscle dynamics. Cardiovasc Res.77 (4), 619–626. 10.1093/cvr/cvm098
24
DunlayS. M.RogerV. L.RedfieldM. M. (2017). Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol.14 (10), 591–602. 10.1038/nrcardio.2017.65
25
DvornikovA. V.BunchT. A.LepakV. C.ColsonB. A. (2023). Fluorescence lifetime-based assay reports structural changes in cardiac muscle mediated by effectors of contractile regulation. J. Gen. Physiol.155 (3), e202113054. 10.1085/jgp.202113054
26
DyckJ. R. B.SossallaS.HamdaniN.CoronelR.WeberN. C.LightP. E.et al (2022). Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J. Mol. Cell Cardiol.167, 17–31. 10.1016/j.yjmcc.2022.03.005
27
GordonA. M.HomsherE.RegnierM. (2000). Regulation of contraction in striated muscle. Physiol. Rev.80 (2), 853–924. 10.1152/physrev.2000.80.2.853
28
GordonA. M.RidgwayE. B. (1993). Cross-bridges affect both TnC structure and calcium affinity in muscle fibers. Adv. Exp. Med. Biol.332, 183–194. 10.1007/978-1-4615-2872-2_17
29
GranzierH.HelmesM.CazorlaO.McNabbM.LabeitD.WuY.et al (2000). “Mechanical properties of titin isoforms,” in Elastic filaments of the cell. Editors GranzierH. L.PollackG. H. (Boston, MA: Springer US), 283–304. 10.1007/978-1-4615-4267-4_17
30
GranzierH.LabeitD.WuY.LabeitS. (2002). Titin as a modular spring: emerging mechanisms for elasticity control by titin in cardiac physiology and pathophysiology. J. Muscle Res. Cell Motil.23 (5–6), 457–471. 10.1023/a:1023458406346
31
GranzierH. L.IrvingT. C. (1995). Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments. Biophys. J.68 (3), 1027–1044. 10.1016/S0006-3495(95)80278-X
32
GreshamK. S.StelzerJ. E. (2016). The contributions of cardiac myosin binding protein C and troponin I phosphorylation to β‐adrenergic enhancement of in vivo cardiac function. J. Physiol.594 (3), 669–686. 10.1113/JP270959
33
HamdaniN.BishuK. G.von Frieling-SalewskyM.RedfieldM. M.LinkeW. A. (2013a). Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res.97 (3), 464–471. 10.1093/cvr/cvs353
34
HamdaniN.FranssenC.LourençoA.Falcão-PiresI.FontouraD.LeiteS.et al (2013c). Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ. Heart Fail6 (6), 1239–1249. 10.1161/CIRCHEARTFAILURE.113.000539
35
HamdaniN.KrysiakJ.KreusserM. M.NeefS.Dos RemediosC. G.MaierL. S.et al (2013b). Crucial role for Ca2+/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ. Res.112 (4), 664–674. 10.1161/CIRCRESAHA.111.300105
36
HarrisS. P.BartleyC. R.HackerT. A.McDonaldK. S.DouglasP. S.GreaserM. L.et al (2002). Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ. Res.90 (5), 594–601. 10.1161/01.res.0000012222.70819.64
37
HeidenreichP. A.BozkurtB.AguilarD.AllenL. A.ByunJ. J.ColvinM. M.et al (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation145 (18), e895–e1032. 10.1161/CIR.0000000000001063
38
HelingLWHJGeevesM. A.KadN. M. (2020). MyBP-C: one protein to govern them all. J. Muscle Res. Cell Motil.41 (1), 91–101. 10.1007/s10974-019-09567-1
39
HelmesM.TrombitásK.CentnerT.KellermayerM.LabeitS.LinkeW. A.et al (1999). Mechanically driven contour-length adjustment in rat cardiac titin’s unique N2B sequence: titin is an adjustable spring. Circ. Res.84 (11), 1339–1352. 10.1161/01.res.84.11.1339
40
HelmesM.Trombita´sK.GranzierH. (1996). Titin develops restoring force in rat cardiac myocytes. Circ. Res.79 (3), 619–626. 10.1161/01.res.79.3.619
41
HinkenA. C.SolaroR. J. (2007). A dominant role of cardiac molecular motors in the intrinsic regulation of ventricular ejection and relaxation. Physiology22 (2), 73–80. 10.1152/physiol.00043.2006
42
HoendermisE. S.LiuL. C. Y.HummelY. M.van der MeerP.de BoerR. A.BergerR. M. F.et al (2015). Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur. Heart J.36 (38), 2565–2573. 10.1093/eurheartj/ehv336
43
HopfA. E.AndresenC.KötterS.IsićM.UlrichK.SahinS.et al (2018). Diabetes-induced cardiomyocyte passive stiffening is caused by impaired insulin-dependent titin modification and can Be modulated by neuregulin-1. Circ. Res.123 (3), 342–355. 10.1161/CIRCRESAHA.117.312166
44
JanssenP. M. L. (2019). Myocardial relaxation in human heart failure: why sarcomere kinetics should be center-stage. Arch. Biochem. Biophys.661, 145–148. 10.1016/j.abb.2018.11.011
45
KampourakisT.YanZ.GautelM.SunY. B.IrvingM. (2014). Myosin binding protein-C activates thin filaments and inhibits thick filaments in heart muscle cells. Proc. Natl. Acad. Sci. U. S. A.111 (52), 18763–18768. 10.1073/pnas.1413922112
46
KanassategaR. S.BunchT. A.LepakV. C.WangC.ColsonB. A. (2022). Human cardiac myosin-binding protein C phosphorylation- and mutation-dependent structural dynamics monitored by time-resolved FRET. J. Mol. Cell Cardiol.166, 116–126. 10.1016/j.yjmcc.2022.02.005
47
KatzA. M. (2011). Physiology of the heart. 5th ed. Philadelphia: Lippincott Williams and Wilkins.
48
KenslerR. W.CraigR.MossR. L. (2017). Phosphorylation of cardiac myosin binding protein C releases myosin heads from the surface of cardiac thick filaments. Proc. Natl. Acad. Sci. U. S. A.114 (8), E1355–E1364. 10.1073/pnas.1614020114
49
KentishJ. C.McCloskeyD. T.LaylandJ.PalmerS.LeidenJ. M.MartinA. F.et al (2001). Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ. Res.88 (10), 1059–1065. 10.1161/hh1001.091640
50
KlabundeR. E. (2022). Cardiovascular physiology concepts. Third edition. Philadelphia: Wolters Kluwer, 265.
51
KnightW. E.WoulfeK. C. (2022). Dysfunctional sarcomeric relaxation in the heart. Curr. Opin. Physiol.26, 100535. 10.1016/j.cophys.2022.100535
52
KobayashiT.SolaroR. J. (2005). Calcium, thin filaments, and the integrative biology of cardiac contractility. Annu. Rev. Physiol.67, 39–67. 10.1146/annurev.physiol.67.040403.114025
53
KonhilasJ. P.IrvingT. C.de TombeP. P. (2002). Frank-Starling law of the heart and the cellular mechanisms of length-dependent activation. Pflugers Arch.445 (3), 305–310. 10.1007/s00424-002-0902-1
54
KooijV.SaesM.JaquetK.ZarembaR.FosterD. B.MurphyA. M.et al (2010). Effect of troponin I Ser23/24 phosphorylation on Ca2+-sensitivity in human myocardium depends on the phosphorylation background. J. Mol. Cell Cardiol.48 (5), 954–963. 10.1016/j.yjmcc.2010.01.002
55
KosiborodM. N.AbildstrømS. Z.BorlaugB. A.ButlerJ.RasmussenS.DaviesM.et al (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med.389 (12), 1069–1084. 10.1056/NEJMoa2306963
56
KosiborodM. N.DeanfieldJ.PratleyR.BorlaugB. A.ButlerJ.DaviesM. J.et al (2024). Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet404 (10456), 949–961. 10.1016/S0140-6736(24)01643-X
57
KraniasE. G.SolaroR. J. (1982). Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart. Nature298 (5870), 182–184. 10.1038/298182a0
58
KrügerM.KötterS.GrütznerA.LangP.AndresenC.RedfieldM. M.et al (2009). Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ. Res.104 (1), 87–94. 10.1161/CIRCRESAHA.108.184408
59
LamC. S. P.RogerV. L.RodehefferR. J.BorlaugB. A.EndersF. T.RedfieldM. M. (2009). Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J. Am. Coll. Cardiol.53 (13), 1119–1126. 10.1016/j.jacc.2008.11.051
60
LandesbergA. (1996). End-systolic pressure-volume relationship and intracellular control of contraction. Am. J. Physiol-Heart Circ. Physiol.270 (1), H338–H349. 10.1152/ajpheart.1996.270.1.H338
61
LeWinterM. M.GranzierH. L. (2014). Cardiac titin and heart disease. J. Cardiovasc Pharmacol.63 (3), 207–212. 10.1097/FJC.0000000000000007
62
LewisG. D.VoorsA. A.Cohen-SolalA.MetraM.WhellanD. J.EzekowitzJ. A.et al (2022). Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial. JAMA328 (3), 259–269. 10.1001/jama.2022.11016
63
LinY.YapE.SivakumarG.TeeN.RamachondraC.HausenloyD. (2022). Cardiac myosin inhibitor, mavacamten, improves myocardial relaxation in mouse HFpEF model. Cardiovasc Res.118 (Suppl. ment_1), cvac066–101. 10.1093/cvr/cvac066.101
64
LinkeW. A. (2023). Stretching the story of titin and muscle function. J. Biomech.152, 111553. 10.1016/j.jbiomech.2023.111553
65
LippiG.Sanchis-GomarF. (2020). Global epidemiology and future trends of heart failure. AME Med. J.5 (0), 15. Available at: https://amj.amegroups.org/article/view/5475.10.21037/amj.2020.03.03
66
LoescherC. M.FreundtJ. K.UngerA.HesselA. L.KühnM.KoserF.et al (2023). Titin governs myocardial passive stiffness with major support from microtubules and actin and the extracellular matrix. Nat. Cardiovasc Res.2 (11), 991–1002. 10.1038/s44161-023-00348-1
67
LoescherC. M.LinkeW. A. (2024). Titin takes centerstage among cytoskeletal contributions to myocardial passive stiffness. Cytoskeleton81 (2–3), 184–187. 10.1002/cm.21827
68
LopaschukG. D.VermaS. (2020). Mechanisms of cardiovascular benefits of sodium glucose Co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl. Sci.5 (6), 632–644. 10.1016/j.jacbts.2020.02.004
69
MamidiR.GreshamK. S.StelzerJ. E. (2014). Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation. Front. Physiol.5, 461. Available at: https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2014.00461/full.10.3389/fphys.2014.00461
70
MamidiR.LiJ.GreshamK. S.VermaS.DohC. Y.LiA.et al (2017). Dose-Dependent effects of the myosin activator omecamtiv mecarbil on cross-bridge behavior and force generation in failing human myocardium. Circ. Heart Fail10 (10), e004257. 10.1161/CIRCHEARTFAILURE.117.004257
71
MartinS. S.AdayA. W.AlmarzooqZ. I.AndersonC. A. M.AroraP.AveryC. L.et al (2024). 2024 heart disease and stroke statistics: a report of US and global data from the American heart association. Circulation149 (8), e347–e913. 10.1161/CIR.0000000000001209
72
MartynD. A.RondinoneJ. F.HuntsmanL. L. (1983). Myocardial segment velocity at a low load: time, length, and calcium dependence. Am. J. Physiol-Heart Circ. Physiol.244 (5), H708–H714. 10.1152/ajpheart.1983.244.5.H708
73
McDonaldK. S.MossR. L. (2000). Strongly binding myosin crossbridges regulate loaded shortening and power output in cardiac myocytes. Circ. Res.87 (9), 768–773. 10.1161/01.res.87.9.768
74
MethawasinM.StromJ. G.SlaterR. E.FernandezV.SaripalliC.GranzierH. (2016). Experimentally increasing the compliance of titin through RNA binding motif-20 (RBM20) inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction. Circulation134 (15), 1085–1099. 10.1161/CIRCULATIONAHA.116.023003
75
MishraS.KassD. A. (2021). Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol.18 (6), 400–423. 10.1038/s41569-020-00480-6
76
MonaskyM. M.VarianK. D.DavisJ. P.JanssenP. M. L. (2008). Dissociation of force decline from calcium decline by preload in isolated rabbit myocardium. Pflugers Arch.456 (2), 267–276. 10.1007/s00424-007-0394-0
77
MossR. L.RazumovaM.FitzsimonsD. P. (2004). Myosin crossbridge activation of cardiac thin filaments: implications for myocardial function in health and disease. Circ. Res.94 (10), 1290–1300. 10.1161/01.RES.0000127125.61647.4F
78
MunJ. Y.PrevisM. J.YuH. Y.GulickJ.TobacmanL. S.BeckP. S.et al (2014). Myosin-binding protein C displaces tropomyosin to activate cardiac thin filaments and governs their speed by an independent mechanism. Proc. Natl. Acad. Sci. U. S. A.111 (6), 2170–2175. 10.1073/pnas.1316001111
79
OmarA. M. S.VallabhajosyulaS.SenguptaP. P. (2015). Left ventricular twist and torsion: research observations and clinical applications. Circ. Cardiovasc Imaging8 (6), e003029. 10.1161/CIRCIMAGING.115.003029
80
OpdahlA.RemmeE. W.Helle-ValleT.EdvardsenT.SmisethO. A. (2012). Myocardial relaxation, restoring forces, and early-diastolic load are independent determinants of left ventricular untwisting rate. Circulation126 (12), 1441–1451. 10.1161/CIRCULATIONAHA.111.080861
81
OstrominskiJ. W.SolomonS. D.VaduganathanM. (2024). Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. Eur. Heart J.45 (30), 2748–2751. 10.1093/eurheartj/ehae414
82
PanB. S.SolaroR. J. (1987). Calcium-binding properties of troponin C in detergent-skinned heart muscle fibers. J. Biol. Chem.262 (16), 7839–7849. 10.1016/s0021-9258(18)47644-2
83
PaulusW. J.TschöpeC. (2013). A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol.62 (4), 263–271. 10.1016/j.jacc.2013.02.092
84
PaulusW. J.TschöpeC.SandersonJ. E.RusconiC.FlachskampfF. A.RademakersF. E.et al (2007). How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J.28 (20), 2539–2550. 10.1093/eurheartj/ehm037
85
PeñaJ. R.WolskaB. M. (2004). Troponin I phosphorylation plays an important role in the relaxant effect of beta-adrenergic stimulation in mouse hearts. Cardiovasc Res.61 (4), 756–763. 10.1016/j.cardiores.2003.12.019
86
PfuhlM.GautelM. (2012). Structure, interactions and function of the N-terminus of cardiac myosin binding protein C (MyBP-C): who does what, with what, and to whom?J. Muscle Res. Cell Motil.33 (1), 83–94. 10.1007/s10974-012-9291-z
87
PonnamS.SevrievaI.SunY. B.IrvingM.KampourakisT. (2019). Site-specific phosphorylation of myosin binding protein-C coordinates thin and thick filament activation in cardiac muscle. Proc. Natl. Acad. Sci. U. S. A.116 (31), 15485–15494. 10.1073/pnas.1903033116
88
PrevisM. J.MunJ. Y.MichalekA. J.PrevisS. B.GulickJ.RobbinsJ.et al (2016). Phosphorylation and calcium antagonistically tune myosin-binding protein C’s structure and function. Proc. Natl. Acad. Sci.113 (12), 3239–3244. 10.1073/pnas.1522236113
89
RadkeM. H.Badillo-LisakowskiV.Britto-BorgesT.KubliD. A.JüttnerR.ParakkatP.et al (2021). Therapeutic inhibition of RBM20 improves diastolic function in a murine heart failure model and human engineered heart tissue. Sci. Transl. Med.13 (622), eabe8952. 10.1126/scitranslmed.abe8952
90
RahmansereshtS.LeeK. H.O’LearyT. S.McNamaraJ. W.SadayappanS.RobbinsJ.et al (2021). The N terminus of myosin-binding protein C extends toward actin filaments in intact cardiac muscle. J. Gen. Physiol.153 (3), e202012726. 10.1085/jgp.202012726
91
ReddyY. N. V.BorlaugB. A. (2016). Heart failure with preserved ejection fraction. Curr. Probl. Cardiol.41 (4), 145–188. 10.1016/j.cpcardiol.2015.12.002
92
ReddyY. N. V.BorlaugB. A. (2021). Pulmonary hypertension in left heart disease. Clin. Chest Med.42 (1), 39–58. 10.1016/j.ccm.2020.11.002
93
RedfieldM. M. (2016). Heart failure with preserved ejection fraction. N. Engl. J. Med.375 (19), 1868–1877. 10.1056/NEJMcp1511175
94
RedfieldM. M.ChenH. H.BorlaugB. A.SemigranM. J.LeeK. L.LewisG.et al (2013). Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA309 (12), 1268–1277. 10.1001/jama.2013.2024
95
RisiC. M.BelknapB.AthertonJ.CoscarellaI. L.WhiteH. D.BryantC. P.et al (2024). Troponin structural dynamics in the native cardiac thin filament revealed by cryo electron microscopy. J. Mol. Biol.436 (6), 168498. 10.1016/j.jmb.2024.168498
96
RobisonP.CaporizzoM. A.AhmadzadehH.BogushA. I.ChenC. Y.MarguliesK. B.et al (2016). Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes. Science352 (6284), aaf0659. 10.1126/science.aaf0659
97
SchulzL.WernerS.BöttnerJ.AdamsV.LurzP.BeslerC.et al (2022). Tubulin expression and modification in heart failure with preserved ejection fraction (HFpEF). Sci. Rep.12, 15734. 10.1038/s41598-022-19766-5
98
SenguptaP. P.TajikA. J.ChandrasekaranK.KhandheriaB. K. (2008). Twist mechanics of the left ventricle: principles and application. JACC Cardiovasc Imaging1 (3), 366–376. 10.1016/j.jcmg.2008.02.006
99
SharmaK.KassD. A. (2014). Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ. Res.115 (1), 79–96. 10.1161/CIRCRESAHA.115.302922
100
ShettigarV.ZhangB.LittleS. C.SalhiH. E.HansenB. J.LiN.et al (2016). Rationally engineered Troponin C modulates in vivo cardiac function and performance in health and disease. Nat. Commun.7 (1), 10794. 10.1038/ncomms10794
101
SlaterR. E.StromJ. G.MethawasinM.LissM.GotthardtM.SweitzerN.et al (2018). Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance. J. Gen. Physiol.151 (1), 42–52. 10.1085/jgp.201812259
102
SolomonS. D.McMurrayJ. J. V.ClaggettB.BoerR. A.DeMetsD.HernandezA. F.et al (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med.387 (12), 1089–1098. 10.1056/NEJMoa2206286
103
StelzerJ. E.DunningS. B.MossR. L. (2006a). Ablation of cardiac myosin-binding protein-C accelerates stretch activation in murine skinned myocardium. Circ. Res.98 (9), 1212–1218. 10.1161/01.RES.0000219863.94390.ce
104
StelzerJ. E.PatelJ. R.MossR. L. (2006b). Protein kinase A-mediated acceleration of the stretch activation response in murine skinned myocardium is eliminated by ablation of cMyBP-C. Circ. Res.99 (8), 884–890. 10.1161/01.RES.0000245191.34690.66
105
Suay-CorrederaC.Alegre-CebolladaJ. (2022). The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C. FEBS Lett.596 (6), 703–746. 10.1002/1873-3468.14301
106
TamargoM.Martínez-LegazpiP.EspinosaM. Á.LyonA.MéndezI.Gutiérrez-IbañesE.et al (2023). Increased chamber resting tone is a key determinant of left ventricular diastolic dysfunction. Circ. Heart Fail16 (12), e010673. 10.1161/CIRCHEARTFAILURE.123.010673
107
TardiffJ. C. (2011). Thin filament mutations: developing an integrative approach to a complex disorder. Circ. Res.108 (6), 765–782. 10.1161/CIRCRESAHA.110.224170
108
TeerlinkJ. R.ClarkeC. P.SaikaliK. G.LeeJ. H.ChenM. M.EscandonR. D.et al (2011). Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet Lond Engl.378 (9792), 667–675. 10.1016/S0140-6736(11)61219-1
109
ThompsonB. R.MartindaleJ.MetzgerJ. M. (2016). Sarcomere neutralization in inherited cardiomyopathy: small-molecule proof-of-concept to correct hyper-Ca2+-sensitive myofilaments. Am. J. Physiol-Heart Circ. Physiol.311 (1), H36–H43. 10.1152/ajpheart.00981.2015
110
TobacmanL. S. (1996). Thin filament-mediated regulation of cardiac contraction. Annu. Rev. Physiol.58, 447–481. 10.1146/annurev.ph.58.030196.002311
111
TongC. W.StelzerJ. E.GreaserM. L.PowersP. A.MossR. L. (2008). Acceleration of crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein C modulates cardiac function. Circ. Res.103 (9), 974–982. 10.1161/CIRCRESAHA.108.177683
112
ToninoP.KissB.StromJ.MethawasinM.SmithJ. E.KolbJ.et al (2017). The giant protein titin regulates the length of the striated muscle thick filament. Nat. Commun.8 (1), 1041. 10.1038/s41467-017-01144-9
113
TsaoC. W.LyassA.EnserroD.LarsonM. G.HoJ. E.KizerJ. R.et al (2018). Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail6 (8), 678–685. 10.1016/j.jchf.2018.03.006
114
VaduganathanM.DochertyK. F.ClaggettB. L.JhundP. S.de BoerR. A.HernandezA. F.et al (2022). SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet400 (10354), 757–767. 10.1016/S0140-6736(22)01429-5
115
van der VeldenJ.StienenG. J. M. (2019). Cardiac disorders and pathophysiology of sarcomeric proteins. Physiol. Rev.99 (1), 381–426. 10.1152/physrev.00040.2017
116
WalcottS.DockenS.HarrisS. P. (2015). Effects of cardiac myosin binding protein-C on actin motility are explained with a drag-activation-competition model. Biophys. J.108 (1), 10–13. 10.1016/j.bpj.2014.11.1852
117
WeithA.SadayappanS.GulickJ.PrevisM. J.VanburenP.RobbinsJ.et al (2012a). Unique single molecule binding of cardiac myosin binding protein-C to actin and phosphorylation-dependent inhibition of actomyosin motility requires 17 amino acids of the motif domain. J. Mol. Cell Cardiol.52 (1), 219–227. Epub 2011 Sep 25. PMID: 21978630; PMCID: PMC3246064. 10.1016/j.yjmcc.2011.09.019
118
WeithA. E.PrevisM. J.HoeprichG. J.PrevisS. B.GulickJ.RobbinsJ.et al (2012b). The extent of cardiac myosin binding protein-C phosphorylation modulates actomyosin function in a graded manner. J. Muscle Res. Cell Motil.33 (6), 449–459. 10.1007/s10974-012-9312-y
119
WongF. L.BunchT. A.LepakV. C.SteedmanA. L.ColsonB. A. (2024). Cardiac myosin-binding protein C N-terminal interactions with myosin and actin filaments: opposite effects of phosphorylation and M-domain mutations. J. Mol. Cell Cardiol.186, 125–137. 10.1016/j.yjmcc.2023.11.010
120
YamadaY.NambaK.FujiiT. (2020). Cardiac muscle thin filament structures reveal calcium regulatory mechanism. Nat. Commun.11 (1), 153. 10.1038/s41467-019-14008-1
121
YamasakiR.WuY.McNabbM.GreaserM.LabeitS.GranzierH. (2002). Protein kinase A phosphorylates titin’s cardiac-specific N2B domain and reduces passive tension in rat cardiac myocytes. Circ. Res.90 (11), 1181–1188. 10.1161/01.res.0000021115.24712.99
122
YellinE. L.NikolicS.FraterR. W. M. (1990). Left ventricular filling dynamics and diastolic function. Prog. Cardiovasc Dis.32 (4), 247–271. 10.1016/0033-0620(90)90016-u
123
ZakeriR.ChamberlainA. M.RogerV. L.RedfieldM. M. (2013). Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation128 (10), 1085–1093. 10.1161/CIRCULATIONAHA.113.001475
124
ZileM. R.BaicuC. F.IkonomidisJ. S.StroudR. E.NietertP. J.BradshawA. D.et al (2015). Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation131 (14), 1247–1259. 10.1161/CIRCULATIONAHA.114.013215
125
ZipesD. P.LibbyP.BonowR. O.MannD. L.TomaselliG. F.BraunwaldE. (Editors) (2019). Braunwald’s heart disease: a textbook of cardiovascular medicine. 11th Edn.Philadelphia: Elsevier, 1944.
126
ZoghbiM. E.WoodheadJ. L.CraigR.PadrónR. (2004). Helical order in tarantula thick filaments requires the “closed” conformation of the myosin head. J. Mol. Biol.342 (4), 1223–1236. 10.1016/j.jmb.2004.07.037
127
ZoghbiM. E.WoodheadJ. L.MossR. L.CraigR. (2008). Three-dimensional structure of vertebrate cardiac muscle myosin filaments. Proc. Natl. Acad. Sci. U. S. A.105 (7), 2386–2390. 10.1073/pnas.0708912105
Summary
Keywords
HFpEF, heart failure with preserved ejection fraction, cMyBP-C, cTnI, cardiac troponin I, titin, diastolic dysfunction, myosin binding protein C
Citation
Dominic KL, Schmidt AV, Granzier H, Campbell KS and Stelzer JE (2024) Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF. Front. Physiol. 15:1512550. doi: 10.3389/fphys.2024.1512550
Received
16 October 2024
Accepted
21 November 2024
Published
12 December 2024
Volume
15 - 2024
Edited by
Jody Martin, University of California, Davis, United States
Reviewed by
Diederik Wouter Dimitri Kuster, Amsterdam University Medical Center, Netherlands
Colleen Kelly, University of Vermont, United States
Updates
Copyright
© 2024 Dominic, Schmidt, Granzier, Campbell and Stelzer.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Katherine L. Dominic, katherine.dominic@case.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.